Publicité
Biotech Finances - L'information stratégique des biodécideurs et des bioinvestisseurs
SEARCH THE SITE
AND ARCHIVES
February 9th, 2010
 Remember me 

BIOTECH FINANCES VIDEO / AUDIO

A LA UNE

VOIR / ECOUTER >>

La journée parlementaire de la biotechnologie : Financer la bioindustrie française de la santé
 
 

NEW

Would you like to have your say on the Eco notes by H. Ella?
Share your comments with us by going to Eco Note.

 
 

BREAKING NEWS

BIOTECH - BIOTECH: LONG LIVE THE HAPPY COUPLE!

"While out-licensing is the spearhead of biotech businesses and the key of their business models, external growth remains an underused path for development in the sector. Most companies have put the matter on hold, but only very few are actually taking action", explains Pierre Kladny, managing partner from Valley Road Capital.

More...

 

LOOK INSIDE

Lettre 445

EXCLUSIVE

All transactions in Europe and Israel of the last six months and previews of the next half year by analysts all over Europe.

More...

 
 

INTERVIEW

BOOSTING THERAPEUTIC INNOVATION: A WINNING STRATEGY FOR EUROPE

Catherine Lassale

Catherine Lassale, dans le n°449 du 08/02/2010

What is the state of therapeutic discoveries in 2010? What is the outlook for the next 10 years? Which levers can we use to develop a competitive European industry? These are far-reaching questions which Dr Catherine Lassale, director of scientific affairs of The French Pharmaceutical Companies Association (LEEM), addresses in Biotech Finances.

BIOTECH FINANCES:

More...

 
 

Recommendations

"Biotech Finances is the only specialized support system in France that gives in-depth information about the medical equipment sector, which is a sector in full development. This is why, for me, it is the best source of information about medtech."

Ismaël Nujurally, CEO, THERACLION

"I appreciate Biotech Finances because it offers both quick information and analysis."

Dr Gilles Avenard, CEO, BIOALLIANCE PHARMA 

Biotech Finances brings us every week the most important information about financial activity and transactions in the biotech sector in Europe. As capital investors we're able to find what we need in less than 10 minutes of reading per week. Bravo!"

Isabelle de Crémoux, General  Partner, Director of Lifesciences Department, SEVENTURE

"Biotech Finances is created with an entrepreneurial spirit and brings together the views of different players in biotechnology financing. In addition to being a comprehensive source of information, it sheds light on what's going on in the background of the sector in Europe."

Jean-Yves Nothias, General Partner, BioConvergence Team, SOCIETE GENERALE ASSET MANAGEMENT

"I never miss an issue of Biotech Finances. It's an excellent vehicle for all the essential information about activity in the sector."

Frédéric Desdouits, Managing Partner at BIONEST- Healthcare Strategic Consulting and M&A.

"For me, Biotech Finances is a unique source of information about the important participants and their strategies in biotech. Biotech Finances has the merit of being able to make a sometimes complex reality understandable in clear and simple words."

Stéphane Olmi , Manager, LAZARD FRERES

"In a sector where information seems to abound, every week Biotech Finances offers a selective, alert and sharp view on the strategy of European pharmaceutical companies and their economic environment. This double treatment, both scientific and business, of the news in life sciences is rare and makes this publication stand out. It is also an excellent decoding tool for professionals."

Bruno Arabian, CEO, MILESTONE

"Biotech Finances is the only specialized support system in France that gives in-depth information about the medical equipment sector, which is a sector in full development. This is why, for me, it is the best source of information about medtech."

Ismaël Nujurally, CEO, THERACLION

Read all Recommendations

 
 
 

Eco Note of the week, as seen by ...

\"Eco
 

Press Releases

 
 
Partenaires
 
 
 
Pub